Regulatory Approvals

FDA Approves Zanidatamab-Based Regimens for First-Line HER2+ Locally Advanced or Metastatic Gastric Cancer

By

Regulatory Approvals — FDA Approves Zanidatamab-Based Regimens for First-Line HER2+ Locally Advanced or Metastatic Gastric Cancer  OncLive

Read the original at Regulatory Approvals ↗

Auto-published by the finit.news Events monitor from Regulatory Approvals; summarized by AI and may contain errors — verify against the primary source. August 25, 2026.

By

Related Post

Regulatory Approvals

Behind the FDA Approval: ‘Historic’ Iberdomide Trial Spotlights MRD End Point and Potential of CELMoDs Across Myeloma

Regulatory Approvals

FDA Approves Zanidatamab Combination Regimens for HER2 Gastric GEJ or Esophageal Cancer

Regulatory Approvals

FDA Approves Ziihera Regimens in First-Line HER2+ Advanced GEA

Financial News For All

Labor

Apple’s rare layoffs hit 147 Bay Area workers

Labor

Hyundai, union reach deal after decade-first full strike as AI job concerns take center stage

Labor

Daily Herald editorial staff announces unionization effort

Regulatory Approvals

FDA approves new Alzheimer’s blood test